Literature DB >> 20082256

Guanxin II (II) for the management of coronary heart disease.

Feng Qin1, Xi Huang.   

Abstract

This article presents an integrated overview of Guanxin II (II) regarding its quality control, pharmacokinetics, pharmacology, clinical studies, adverse events, dosage and administration, and its pharmacoeconomic assessment. It has been demonstrated that Guanxin II has beneficial effects on coronary heart disease (CHD). The underlying mechanism was proved to be its anti-ischemic, anti-apoptotic, antioxidative, antiplatelet and anti-inflammatory effects, and so on. Tanshinol, hydroxysafflor yellow A and ferulic acid might be responsible for the cardioprotective effect of Guanxin II. In terms of acquisition cost, Guanxin II is cheaper than other drugs currently available for CHD. Guanxin II is safe, cheap, and effective in the management of CHD. However, the mechanism of its cardioprotective effects has not been completely understood because of limitations in the research methodologies of Chinese medicine. Further work should be carried out with single components such as tanshinol, hydroxysafflor yellow A and ferulic acid, using modern biochemical and molecular methods.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20082256     DOI: 10.1007/s11655-009-0472-6

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  26 in total

Review 1.  Clinical practice. Chronic stable angina.

Authors:  Jonathan Abrams
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

2.  [Effect of guanxin no. 2 on gene variant expression profile in rats after myocardial ischemia].

Authors:  Cheng-Yao Yu; Hui-Li Gao; Zhen Liu
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2008-05

3.  [The effect of compositus Guan-Xin NO 2 on myocardial ischaemia and hypoxia in experimental animals (author's transl)].

Authors:  L N Xu; Z Z Yin; Y R Ou
Journal:  Yao Xue Xue Bao       Date:  1979-08

4.  Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Authors:  Thomas Thom; Nancy Haase; Wayne Rosamond; Virginia J Howard; John Rumsfeld; Teri Manolio; Zhi-Jie Zheng; Katherine Flegal; Christopher O'Donnell; Steven Kittner; Donald Lloyd-Jones; David C Goff; Yuling Hong; Robert Adams; Gary Friday; Karen Furie; Philip Gorelick; Brett Kissela; John Marler; James Meigs; Veronique Roger; Stephen Sidney; Paul Sorlie; Julia Steinberger; Sylvia Wasserthiel-Smoller; Matthew Wilson; Philip Wolf
Journal:  Circulation       Date:  2006-01-11       Impact factor: 29.690

5.  Pharmacokinetic interactions between warfarin and kangen-karyu, a Chinese traditional herbal medicine, and their synergistic action.

Authors:  Toshiaki Makino; Hannosuke Wakushima; Takuya Okamoto; Yasuhiro Okukubo; Yoshiharu Deguchi; Yoshihiro Kano
Journal:  J Ethnopharmacol       Date:  2002-09       Impact factor: 4.360

6.  SPE-HPLC method for the determination and pharmacokinetic studies on paeoniflorin in rat serum after oral administration of traditional Chinese medicinal preparation Guan-Xin-Er-Hao decoction.

Authors:  Guan Ye; Yin-Zeng Li; Yan-Yan Li; Hong-Zhu Guo; De-An Guo
Journal:  J Pharm Biomed Anal       Date:  2003-10-15       Impact factor: 3.935

7.  Cardioprotection by Guanxin II in rats with acute myocardial infarction is related to its three compounds.

Authors:  Xi Huang; Feng Qin; Hong-Min Zhang; Hong-Bin Xiao; Long-Xin Wang; Xue-Ya Zhang; Ping Ren
Journal:  J Ethnopharmacol       Date:  2008-11-08       Impact factor: 4.360

8.  Pharmacokinetic comparison of puerarin after oral administration of Jiawei-Xiaoyao-San to healthy volunteers and patients with functional dyspepsia: influence of disease state.

Authors:  Feng Qin; Xi Huang; Hong-Min Zhang; Ping Ren
Journal:  J Pharm Pharmacol       Date:  2009-01       Impact factor: 3.765

9.  [Effects of guanxin II on cardiac protein expression after acute myocardial ischemia on rats].

Authors:  Cheng-Yao Yu; Zhen Liu; Xin-Min Xu; Yi-Kui Li; Lian-Da Li
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  2008-07

Review 10.  Current antiplatelet therapies: benefits and limitations.

Authors:  Dominick J Angiolillo; Luis A Guzman; Theodore A Bass
Journal:  Am Heart J       Date:  2008-08       Impact factor: 4.749

View more
  6 in total

1.  A novel oral preparation of hydroxysafflor yellow A base on a chitosan complex: a strategy to enhance the oral bioavailability.

Authors:  Guan-nan Ma; Fang-lin Yu; Shan Wang; Zhi-ping Li; Xiang-yang Xie; Xing-guo Mei
Journal:  AAPS PharmSciTech       Date:  2014-12-16       Impact factor: 3.246

2.  Enhanced absorption of hydroxysafflor yellow A using a self-double-emulsifying drug delivery system: in vitro and in vivo studies.

Authors:  Liang-Zhong Lv; Chen-Qi Tong; Qing Lv; Xin-Jiang Tang; Li-Ming Li; Qing-Xia Fang; Jia Yu; Min Han; Jian-Qing Gao
Journal:  Int J Nanomedicine       Date:  2012-07-30

3.  A Systems Biology Approach to Characterize Biomarkers for Blood Stasis Syndrome of Unstable Angina Patients by Integrating MicroRNA and Messenger RNA Expression Profiling.

Authors:  Jie Wang; Gui Yu
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-14       Impact factor: 2.629

4.  Mechanism of enhanced oral absorption of hydrophilic drug incorporated in hydrophobic nanoparticles.

Authors:  Liang-Zhong Lv; Chen-Qi Tong; Jia Yu; Min Han; Jian-Qing Gao
Journal:  Int J Nanomedicine       Date:  2013-07-29

5.  Danshen-Chuanxiong-Honghua Ameliorates Cerebral Impairment and Improves Spatial Cognitive Deficits after Transient Focal Ischemia and Identification of Active Compounds.

Authors:  Xianhua Zhang; Wan Zheng; Tingrui Wang; Ping Ren; Fushun Wang; Xinliang Ma; Jian Wang; Xi Huang
Journal:  Front Pharmacol       Date:  2017-07-18       Impact factor: 5.810

6.  Cardioprotective effects and underlying mechanism of Radix Salvia miltiorrhiza and Lignum Dalbergia odorifera in a pig chronic myocardial ischemia model.

Authors:  Rui Lin; Jialin Duan; Fei Mu; Haixu Bian; Meina Zhao; Min Zhou; Yao Li; Aidong Wen; Yong Yang; Miaomiao Xi
Journal:  Int J Mol Med       Date:  2018-08-27       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.